Real-time Estimate
Cboe BZX
03:58:04 2024-06-04 pm EDT
|
5-day change
|
1st Jan Change
|
6.45
USD
|
-1.53%
|
|
-0.38%
|
-26.92%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,609
|
817.2
|
757.3
|
-
|
-
|
Enterprise Value (EV)
1 |
1,450
|
695.5
|
680.4
|
552
|
374.6
|
P/E ratio
|
-4.43
x
|
-4.06
x
|
-3.91
x
|
-4.34
x
|
-4.39
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
170
x
|
207
x
|
104
x
|
EV / Revenue
|
-
|
-
|
153
x
|
151
x
|
51.4
x
|
EV / EBITDA
|
-12.7
x
|
-3.42
x
|
-3.37
x
|
-2.25
x
|
-1.21
x
|
EV / FCF
|
-9.8
x
|
-3.99
x
|
-3.54
x
|
-2.66
x
|
-1.66
x
|
FCF Yield
|
-10.2%
|
-25%
|
-28.3%
|
-37.6%
|
-60.1%
|
Price to Book
|
5.71
x
|
6.06
x
|
3.84
x
|
3.71
x
|
2.59
x
|
Nbr of stocks (in thousands)
|
86,611
|
92,230
|
115,625
|
-
|
-
|
Reference price
2 |
18.58
|
8.860
|
6.550
|
6.550
|
6.550
|
Announcement Date
|
3/9/23
|
3/1/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
4.442
|
3.653
|
7.284
|
EBITDA
1 |
-
|
-114.3
|
-203.5
|
-201.7
|
-245.3
|
-310.7
|
EBIT
1 |
-
|
-116.5
|
-204.8
|
-202.5
|
-227
|
-259.1
|
Operating Margin
|
-
|
-
|
-
|
-4,557.73%
|
-6,214.31%
|
-3,557.67%
|
Earnings before Tax (EBT)
1 |
-165.9
|
-122.8
|
-198.4
|
-192.5
|
-214.5
|
-232.1
|
Net income
1 |
-165.4
|
-142
|
-198.1
|
-192.6
|
-214.6
|
-231.8
|
Net margin
|
-
|
-
|
-
|
-4,335.1%
|
-5,874.05%
|
-3,181.9%
|
EPS
2 |
-
|
-4.190
|
-2.180
|
-1.677
|
-1.509
|
-1.492
|
Free Cash Flow
1 |
-
|
-147.9
|
-174.1
|
-192.2
|
-207.6
|
-225
|
FCF margin
|
-
|
-
|
-
|
-4,327.49%
|
-5,682.73%
|
-3,089.43%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/7/22
|
3/9/23
|
3/1/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
0.591
|
1.358
|
0.3
|
0.3364
|
-
|
-
|
EBITDA
1 |
-
|
-
|
-38.98
|
-
|
-
|
-63.39
|
-47.03
|
-48.04
|
-48.48
|
-48.94
|
-
|
-
|
EBIT
1 |
-31.66
|
-38.69
|
-40.03
|
-45.26
|
-51.46
|
-68.04
|
-48.34
|
-49.4
|
-50.81
|
-52.32
|
-62.07
|
-50.96
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-8,179.53%
|
-3,637.03%
|
-16,937.55%
|
-15,554.13%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-39.47
|
-39.6
|
-42.35
|
-50.82
|
-65.64
|
-45.63
|
-48.12
|
-48.95
|
-49.68
|
-50.65
|
-50.96
|
Net income
1 |
-
|
-40.6
|
-39.4
|
-42.38
|
-50.71
|
-65.64
|
-45.76
|
-48.13
|
-48.97
|
-49.7
|
-50.65
|
-50.96
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-7,742.98%
|
-3,543.2%
|
-16,321.83%
|
-14,775.23%
|
-
|
-
|
EPS
2 |
-1.610
|
-
|
-0.4400
|
-0.4700
|
-0.5500
|
-0.7200
|
-0.4400
|
-0.4064
|
-0.4119
|
-0.4084
|
-0.3900
|
-0.3900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/14/22
|
3/9/23
|
5/11/23
|
8/7/23
|
11/3/23
|
3/1/24
|
5/10/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
159
|
122
|
77
|
205
|
383
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-148
|
-174
|
-192
|
-208
|
-225
|
ROE (net income / shareholders' equity)
|
-
|
-177%
|
-88.2%
|
-138%
|
-134%
|
-98.2%
|
ROA (Net income/ Total Assets)
|
-
|
-42.9%
|
-71.5%
|
-78.6%
|
-65.3%
|
-64.2%
|
Assets
1 |
-
|
331.1
|
277.1
|
245
|
328.4
|
361
|
Book Value Per Share
2 |
-
|
3.250
|
1.460
|
1.710
|
1.760
|
2.530
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
16.1
|
8.72
|
8.41
|
9.37
|
10.9
|
Capex / Sales
|
-
|
-
|
-
|
189.39%
|
256.46%
|
149.92%
|
Announcement Date
|
3/7/22
|
3/9/23
|
3/1/24
|
-
|
-
|
-
|
Last Close Price
6.55
USD Average target price
14.18
USD Spread / Average Target +116.52% Consensus |
1st Jan change
|
Capi.
|
---|
| -26.92% | 757M | | +16.82% | 121B | | +13.16% | 107B | | -5.40% | 24.82B | | +1.69% | 22.48B | | -10.09% | 18.32B | | -40.52% | 16.33B | | -14.29% | 15.31B | | +1.92% | 14.08B | | +24.22% | 11.74B |
Bio Therapeutic Drugs
|